A biological mechanism that can explain the finding of a risk reduction of oesophageal adenocarcinoma after discontinuation of PPI therapy is normalization of the elevated gastrin levels associated with long-term PPI use [25, 26]. Here, GAST is linked to esophageal adenocarcinoma.